![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Dthera’s Digital Alzheimer’s Treatment Granted Breakthrough Designation
Dthera’s Digital Alzheimer’s Treatment Granted Breakthrough Designation
![](https://www.fdanews.com/ext/resources/test/Device_Images6/DtheraSciences_Logo.gif?t=1535145068&width=430)
August 24, 2018
The FDA granted Dthera Sciences breakthrough designation for its digital Alzheimer’s treatment, one of the first digital therapeutic products to receive the designation.
The digital device uses a custom-built tablet, equipped with a camera, to display memories relevant to the patient, such as photos of loved ones.
Artificial intelligence built into the device gauges the patient’s reaction to the displayed memories and adjusts content on the screen to guide the patient’s emotions.
Upcoming Events
-
21Oct